Background and Purpose: Protein C and protein S have been found reduced in some patients with ischemic cerebrovascular diseases, but the relevance of this finding for prognosis is unsettled.
In recent years there has been a renewed surge of interest in the relation between disorders of the coagulation system and ischemic cerebrovascular diseases with the twofold aim of identifying possible congenital deficiencies predisposing to thrombosis and identifying derangements of the coagulation pathway related to stroke, thus making these goals useful predictive tools.1 Protein C and protein S are two vitamin K-dependent plasma proteins involved in the anticoagulant pathway. On activation in vivo by thrombin complexed to endothelial thrombomodulin, protein C inhibits blood coagulation through selectively inactivating factors Va and Vllla in cooperation with free protein S (ie, the amount of protein S not bound to C4bBP).
Congenital deficiencies of either protein C or protein S cause recurrent venous thrombotic episodes,2-5 and anecdotal observations have suggested a causal link between congenital deficiencies and cerebral infarction. [6] [7] [8] [9] However, conflicting results have been published about patients with ischemic atherothrombotic strokes. Some authors found an inverse relation between mortality and protein C plasma levels in acute stroke,10 whereas others have not confirmed such an association.1" Similarly, Sacco et In this investigation, we prospectively evaluated the temporal profile of plasma proteins C and S in a consecutive series of acute stroke patients to assess whether proteins C and S correlate with stroke severity or outcome.
Materials and Methods
Forty-three consecutive patients admitted to the Clinica Neurologica of Brescia for a first-ever ischemic stroke, as assessed by computed tomography, were evaluated within 3 to 30 hours (mean, 16 hours) after stroke onset. These patients represent the whole sample group of first-ever ischemic strokes admitted to our ward from the casualty department over 6 months. We tried to exclude all patients with acquired conditions liable to reduce the plasma levels of protein C, protein S, or both. Patients excluded included those taking anticoagulant drugs (n=4) and contraceptives (n=1) and those with collagen diseases (n=2), liver failure (n=3), or a case history suggesting a possible genetic deficit (n= 1).9,14,15 The sample group included 27 men (mean age, 57.3 years; range, 49 to 81 years) and 16 women (mean age, 56.7 years; range, 35 to 78 years).
On admission, the known risk factors for ischemic stroke were recorded, including hypertension, diabetes, tobacco and alcohol consumption, dyslipidemia, and emboligenic heart disease (atrial fibrillation, mitral valve insufficiency, and myocardial infarction within the past 6 months). Lesion size was determined from computed tomography obtained, on average, 10 days (range, 5 to 19 days) after stroke. Considering the concentration of the variable of interest at the first sampling, the patients were subdivided into two groups: normal (protein C or free protein S) and low (protein C or free protein S). The two classes were then compared for the remaining variables, using the t test, Fisher's exact test, and odds ratio when appropriate.
Results
At the first sampling, abnormally low levels of protein C (Table 1) were found in 6 of 43 patients (14% of sample group). In these patients, the mean protein C value was 46+3%, whereas in the remaining 37 patients the mean value was 93+±7%. Postonset sampling time was the same in normal as in deficient cases (10±6 versus 11±8 hours, respectively).
The patients in the low protein C class had, on admission, a mean Barthel score of 44±44, a mean CaNeSc score of 5.41+4, and a mean lesion size of 28±52 mL. Four of six (66.7%) had emboligenic heart disease (two nonvalvular atrial fibrillation, one atrial fibrillation with mitral insufficiency, and one recent myocardial infarction). Transthoracic echocardiography showed intracardiac thrombus in one patient and mitral thickening in another. Two patients died during the hospital stay because of massive brain swelling.
At the 2-month follow-up, three of the four survivors still had subnormal protein C concentrations (57%, 65%, and 31%). At the 6-month follow-up, one more patient (protein C, 31% at 2 months) had died because of recurrent stroke, raising the overall mortality to 50%. Among the three survivors, two had returned to normal protein C, The patients with normal protein C on admission had a mean score of 75±32 on the Barthel scale, 8 .7±3 on the CaNeSc scale, and a mean lesion size of 8±22 mL. The prevalence of emboligenic cardiac disease was 8.1% (3 of 37) (two atrial fibrillation and one recent myocardial infarction). Three died in the hospital (one from pulmonary embolism, one because of myocardial infarction, and one because of massive brain swelling).
At subsequent follow-up, 11 patients (four at 2 months and seven at 6 months) were excluded because of unwillingness to undertake the blood sampling. However, telephone inquiries ascertained they were all alive at 6 months. All 23 remaining patients maintained normal protein C levels at 2 and 6 months (89±13% and 95 + 13%, respectively). No further deaths were recorded, thus resulting in an overall mortality of 8.1%.
In the 23 patients examined at 6 months, the clinical outcome was good, with a mean Barthel score of 95±9 and a mean CaNeSc score of 11.19±3.
The statistical comparison between patients with low and normal protein C on admission showed that the former were more impaired on the clinical severity scores, had a higher prevalence of emboligenic heart disease, and had higher mortality at six months. No other vascular risk factor was statistically different in the two groups.
If the 11 patients lost at follow-up are excluded, the mortality in the normal baseline group increases to 12% (three of 26) and the proportion of emboligenic heart disease to 12%, but the difference between normal and deficient cases is still significant (mortality, 50% versus 12%; Fisher's exact test, P=.034; emboligenic heart disease, 66.7% versus 12%; Fisher's exact test, P=.01).
Finally, multiple regression analysis showed that baseline protein C values correlated with free protein S concentrations (/3, .572; t, 3.187; P, .0034), whereas age, lesion size, Barthel score, CaNeSc score, hypertension, cholesterol, triglycerides, prothrombin time, hematocrit, and tobacco and alcohol consumption had no effect.
Low free protein S levels were found at entry in eight patients (Table 2) , with a mean free protein S value of 58±2%, whereas the remaining 35 patients had a mean free protein S concentration of 93+7%. The sampling time did not differ between normal (12±8 hours) and low (14±10 hours) free protein S patients. On multiple regression analysis, baseline free protein S correlated to protein C but to no other variable.
On admission, there was no statistical difference in either comparison between low and normal free protein S patients. Similarly, mortality at 6 months was approximately the same in both groups (1 of 8, 12.5% in low free protein S patients; 5 of 35, 14.2% in normal free protein S patients).
Because of patients who had dropped out, the study protocol was completed in 20 of the surviving patients with initially normal free protein S and in six with initially low free protein S. In the former group, four patients at the 2-month and three at the 6-month follow-ups had a decrease in free protein S values below normal but had no sign of relapse or other relevant disease. In contrast, all patients with low free protein S levels on admission returned to normal within the 6 months.
Final Barthel score was 94±15 in low free protein S patients and 92±24 in normal free protein S patients. The corresponding values for CaNeSc score were 8.9 ±2 and 9.1±3, respectively. Neither difference was statistically significant.
Finally, two of the eight patients with low initial free protein S also had abnormally low protein C. One of these patients died, whereas the second patient had normal protein C and free protein S values at the 6-month follow-up.
Discussion
Of the patients included in this study, 14% had abnormally low protein C plasma concentrations. Compared with those who had normal protein C, these patients were more severely impaired and had a statistically higher 6-month mortality rate.
An association between protein C and mortality was described by D'Angelo et al10 in a study in which protein C, assessed within 48 hours of the stroke, was lower in patients who did not survive 2 months than in survivors at the same time. By contrast, no abnormality was found by Chancellor et al'3 in 38 patients younger than 40 years, but in this study the sampling was performed at a mean of 36 months after stroke; thus, patient selection is biased by the exclusion of patients who died early. In the present study, protein C was measured soon after stroke in all patients and at 2 and 6 months in most survivors, and the results indicate that low protein C levels predict the worst outcome.
The reason for the finding of low protein C levels in some patients cannot be presently clarified. One possibility is that, despite the care to rule out congenital deficiencies, some cases were nonetheless inadvertently included. The other possibility is that stroke itself caused a reduction in the measurable levels of protein C, analogous to what has been found for other coagulation factors such as fibrinopeptide A,18-20 especially in patients with atrial fibrillation,2' the proportion of whom was actually higher in the low protein C group.
Regardless of the mechanism, our results suggest that low levels of protein C in acute stroke patients are predictive of unfavorable outcome. Early recognition of these patients might help in the identification of those patients who are at greatest risk of early death or recurrence and for whom early anticoagulation might be considered.18 This conclusion is based, however, on a small series. A larger prospective, rigidly controlled study is needed to definitively answer the question.
The prevalence of patients with low baseline levels of free protein S was 18.4% (eight of 45 patients). This group was no different from the remaining sample for either variable considered. The temporal course of free protein S, at variance with protein C, was uneven. In fact, free protein S concentration fell below normal in some patients in which it was normal on admission (four at the second sampling and three at the third sampling), whereas it returned to normal in six survivors of the group with initially low levels (one survivor was lost at the 6-month follow-up). the method of determination of free protein S is inaccurate at the lower end of the normality range, so that free protein S might be actually underestimated. As a consequence, five of eight patients with free protein S levels between 60% and 70% would have been misclassified as abnormal (Figure) . However, the proportion of patients with low free protein S in this study (18.4%) is approximately the same as that reported by Sacco et al'2 (20%), who used a different method of determination. Therefore, we would view this interpretation as unlikely. The relatively high prevalence of patients with low free protein S suggests that the ischemic event might be related to the decrease in free protein S, probably interfering with the free-to-bound ratio of protein S. C4bBP is an acute-phase reactant, and an increase in its concentration that could occur in some patients in response to the acute phase of stroke would have, as a consequence, the reciprocal decrease in the amount of free protein S. Therefore, low levels of free protein S in early stroke could reflect a nonspecific response to an acute event rather than a specific marker of activation of thrombotic mechanisms. Some evidence supporting this interpretation is provided by the finding that among seven patients with an initial elevated erythrocyte sedimentation rate (another acute-phase reactant) four had free protein S levels below 75%.
It is unclear whether the resulting lowering of free protein S may in turn facilitate thrombus formation. Despite a relatively short follow-up, our findings do not indicate that reductions of free protein S worsen the prognosis of stroke, because there was no statistical difference between low and normal free protein S patients either in severity scores or in mortality, as shown in Table 2 .
Finally, the uneven temporal profile of free protein S concentration suggests that complex factors, partly un-1
